KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) Research & Development (2017 - 2025)

Historic Research & Development for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to $90.0 million.

  • Guardant Health's Research & Development rose 303.64% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.5 million, marking a year-over-year increase of 447.7%. This contributed to the annual value of $347.8 million for FY2024, which is 529.45% down from last year.
  • Latest data reveals that Guardant Health reported Research & Development of $90.0 million as of Q3 2025, which was up 303.64% from $87.4 million recorded in Q2 2025.
  • Guardant Health's Research & Development's 5-year high stood at $106.6 million during Q4 2022, with a 5-year trough of $55.5 million in Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $87.4 million (2025), whereas its average is $85.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 9580.08% in 2021, then tumbled by 1568.99% in 2023.
  • Guardant Health's Research & Development (Quarter) stood at $73.0 million in 2021, then soared by 45.96% to $106.6 million in 2022, then fell by 15.69% to $89.9 million in 2023, then rose by 4.1% to $93.5 million in 2024, then dropped by 3.83% to $90.0 million in 2025.
  • Its last three reported values are $90.0 million in Q3 2025, $87.4 million for Q2 2025, and $88.5 million during Q1 2025.